Rectal Indomethacin to Prevent Post ESWL-pancreatitis

Rectally Administered Indomethacin to Prevent Post-ESWL-pancreatitis (RIPEP)

The purpose of the study is to determine whether rectal indomethacin reduces the incidence of post-ESWL pancreatitis.

It is a prospective, double-blind, randomized controlled trial. Patients with painful chronic pancreatitis and pancreatic stones (> 5 mm in diameter) who are treated with ESWL at Changhai Hospital will be randomly allocated to indomethacin or placebo therapy before the procedure.

Inclusion Criteria:

• any patient with chronic pancreatitis and pancreatic stones (> 5 mm in diameter) undergoing P-ESWL
• at least 18 years old
• provides informed consent

Exclusion Criteria:

• readmitted to the hospital during the enrollment of the study
• contraindications to ESWL
• suspected or established malignancy
• pancreatic ascites
• receiving NSAIDs within 7 days
• contraindication to NSAIDs (including gastrointestinal hemorrhage within 4 weeks or renal dysfunction with serum creatinine >120 μmol/L)
• presence of coagulopathy or received anticoagulation therapy within 3 days
• acute pancreatitis within 3 days
• known active cardiovascular or cerebrovascular disease
• pregnant or breastfeeding women
• without a rectum (ie, status post-total proctocolectomy)